However, the finding is in contrary to the clinical observation that lower USP18 expression correlates with higher MS severity [16], indicating that mutations of USP18 in other cell populations, rather than CD4+ T cells, might be responsible for MS pathogenesis. The gene discussed is CD4; the disease is myeloid sarcoma.